Free Trial
→ You’re Being LIED To About The Iran War (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:ADAG

Adagene Q4 2025 Earnings Report

Adagene logo
$3.69 +0.11 (+3.07%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$3.66 -0.02 (-0.68%)
As of 05/8/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Adagene EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.28
Beat/Miss
Beat by +$0.24
One Year Ago EPS
N/A

Adagene Revenue Results

Actual Revenue
$3.84 million
Expected Revenue
$17.50 million
Beat/Miss
Missed by -$13.66 million
YoY Revenue Growth
N/A

Adagene Announcement Details

Quarter
Q4 2025
Date
4/1/2026
Time
Before Market Opens
Conference Call Date
Wednesday, April 1, 2026
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Adagene's Q4 2025 Press ReleasePress Release
(6-K)
Adagene's Q4 2025 Annual reportAnnual report
(20-F)

Adagene Earnings Headlines

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
April 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/adagene-presents-two-posters-aacr-200100813.html
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types
April 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/17/3276474/0/en/adagene-presents-two-posters-at-aacr-2026-with-new-data-highlighting-muzastotug-s-potential-as-a-backbone-combination-therapy-for-multiple-tumor-types.html
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
May 9 at 1:00 AM  |  Profits Run (Ad)
Adagene Looks Attractive With ADG126 And Validating Partnerships
April 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4891338-adagene-looks-attractive-with-adg126-and-validating-partnerships
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
April 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/14/3273199/0/en/adagene-adds-industry-veteran-peter-lebowitz-to-scientific-and-strategic-advisory-board.html
Why is ADAG stock tanking pre-market today?
April 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/why-is-adag-stock-tanking-pre-market-today/ar-AA1ZZIU7
See More Adagene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adagene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adagene and other key companies, straight to your email.

About Adagene

Adagene (NASDAQ:ADAG) Inc., headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability. The immunome platform enables rapid identification of high-quality antibody candidates derived from healthy donor B cells, while the AI-driven design engine accelerates selection and engineering, aiming to streamline candidate advancement toward investigational new drug filings and clinical trials.

Adagene operates research facilities in Suzhou and maintains an office in Cambridge, Massachusetts, serving global markets through strategic collaborations with leading pharmaceutical partners. The company’s leadership team is led by founder and CEO Dr. Ying Yan, whose expertise in antibody discovery and immuno-oncology has driven the development of its platform-based strategy. Under her guidance, Adagene has expanded its research capabilities and advanced multiple therapeutic candidates into the clinic.

View Adagene Profile
Earnings Tools